COPD: Journal of Chronic Obstructive Pulmonary Disease

2021 Worldwide Chronic Obstructive Pulmonary Disease Industry Report - Featuring Afimmune, Allakos and Astellas Pharma Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, May 21, 2021
Health, Pharmaceutical, COPD: Journal of Chronic Obstructive Pulmonary Disease, Chronic condition, Publications, Pulmonary disease, chronic obstructive, severe early-onset, Chronic lung disease

b'The "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Chronic obstructive pulmonary disease pipeline landscape.

Key Points: 
  • b'The "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Chronic obstructive pulmonary disease pipeline landscape.
  • It covers the pipeline drug profiles, including clinical and nonclinical stage products.
  • It further highlights the inactive pipeline products in this space.\nThe companies and academics are working to assess challenges and seek opportunities that could influence Chronic obstructive pulmonary disease R&D.
  • The therapies under development are focused on novel approaches to treat/improve Chronic obstructive pulmonary disease.\nThis segment of the Chronic obstructive pulmonary disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.

PAOG Confirms CBD Nutraceutical Q4 Revenue Plans

Retrieved on: 
Tuesday, May 11, 2021
Health sciences, Health, Articles, Food science, Nutraceutical, Nutrition, Pharmacy, CBD, Cannabis, Chronic obstructive pulmonary disease, COPD: Journal of Chronic Obstructive Pulmonary Disease

b'Sandusky, Ohio--(Newsfile Corp. - May 11, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed plans to introduce three CBD Nutraceutical Products beginning in the fourth quarter of this year, 2021.\nOn Friday, PAOG released a preview of the company\'s plan to launch a CBD Nutraceuticals line of products.

Key Points: 
  • b'Sandusky, Ohio--(Newsfile Corp. - May 11, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed plans to introduce three CBD Nutraceutical Products beginning in the fourth quarter of this year, 2021.\nOn Friday, PAOG released a preview of the company\'s plan to launch a CBD Nutraceuticals line of products.
  • PAOG\'s CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments.\nPAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties.
  • Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above.

PAOG 2021 CBD Nutraceuticals Sales Plan Preview This Friday To Include ALKM and USMJ Partnership Highlights

Retrieved on: 
Thursday, May 6, 2021
Herbalism, Medicinal plants, Health sciences, Health, Chronic lower respiratory diseases, Medicine, COPD: Journal of Chronic Obstructive Pulmonary Disease, Cannabis, Medical cannabis, Chronic obstructive pulmonary disease, Forward-looking statement

RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.

Key Points: 
  • RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.
  • Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.\n'

PAOG 2021 CBD Nutraceuticals Rollout Preview This Friday

Retrieved on: 
Wednesday, May 5, 2021
Medicinal plants, Psychoactive drugs, Euphoriants, Entheogens, Health sciences, Herbalism, Cannabis smoking, Health, COPD: Journal of Chronic Obstructive Pulmonary Disease, Cannabis, Chronic obstructive pulmonary disease, Medical cannabis

b'Sandusky, Ohio--(Newsfile Corp. - May 5, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed a CBD Nutraceutical Sales Rollout Presentation scheduled this Friday, May 7, 2021.\nLast year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).

Key Points: 
  • b'Sandusky, Ohio--(Newsfile Corp. - May 5, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed a CBD Nutraceutical Sales Rollout Presentation scheduled this Friday, May 7, 2021.\nLast year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
  • RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.\n'

PAOG CBD Nutraceuticals to Hit Market This Year

Retrieved on: 
Tuesday, May 4, 2021
Medicinal plants, Psychoactive drugs, Euphoriants, Entheogens, Health sciences, Herbalism, Cannabis smoking, Health, COPD: Journal of Chronic Obstructive Pulmonary Disease, Cannabis, Chronic obstructive pulmonary disease, Medical cannabis

b'Sandusky, Ohio--(Newsfile Corp. - May 4, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed plans to present the Company\'s CBD Nutraceutical Sales Rollout Plan this Friday, May 7, 2021.\nLast year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).

Key Points: 
  • b'Sandusky, Ohio--(Newsfile Corp. - May 4, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed plans to present the Company\'s CBD Nutraceutical Sales Rollout Plan this Friday, May 7, 2021.\nLast year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
  • RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • 9,199,960 entitled, "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.\n'

PAOG 2021 CBD Nutraceutical Sales Rollout Plan Presentation Scheduled This Friday

Retrieved on: 
Monday, May 3, 2021
Medicinal plants, Psychoactive drugs, Euphoriants, Entheogens, Health sciences, Herbalism, Cannabis smoking, Health, COPD: Journal of Chronic Obstructive Pulmonary Disease, Cannabis, Chronic obstructive pulmonary disease, Medical cannabis

b'Sandusky, Ohio--(Newsfile Corp. - May 3, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced plans to present the company\'s CBD Nutraceutical Sales Rollout Plan this Friday, May 7, 2021.\nLast year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).

Key Points: 
  • b'Sandusky, Ohio--(Newsfile Corp. - May 3, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced plans to present the company\'s CBD Nutraceutical Sales Rollout Plan this Friday, May 7, 2021.\nLast year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
  • RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.\n'

AI Cluster Modeling on COVID-19 Data at Scale Offers Opportunity for Improved Patient Outcomes

Retrieved on: 
Friday, April 30, 2021
Chronic lower respiratory diseases, Medical terminology, Medicine, Chronic obstructive pulmonary disease, COPD: Journal of Chronic Obstructive Pulmonary Disease, Health, Chronic condition, Respiratory disease, Domain driven data mining

With access to historical patient data and sustained monitoring of potential "long-Covid" symptoms as they emerge, medical practitioners are able to rapidly identify patterns and optimize response.\nDr.

Key Points: 
  • With access to historical patient data and sustained monitoring of potential "long-Covid" symptoms as they emerge, medical practitioners are able to rapidly identify patterns and optimize response.\nDr.
  • Vafa Bayat, Bitscopic\'s Head of R&D, said: "By highlighting best practices specific to subpopulations, we can better personalize care.
  • For example, older patients tend to present with pre-existing chronic conditions such as congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD).
  • Bitscopic\'s Praedico platform integrates electronic health data from the VA\'s 160+ hospitals with 9 unique million patient records in near-real time, and translates this data into actionable insights and alerts.

Global Smart Inhalers Market (2020 to 2025) - by Components, Product, Application, Distribution Channel, End-use and Geography

Retrieved on: 
Tuesday, April 20, 2021
Respiratory therapy, Health sciences, Health, Dosage forms, Chronic lower respiratory diseases, Asthma, Inhaler, Nebulizer, Chronic obstructive pulmonary disease, Respiratory disease, COPD: Journal of Chronic Obstructive Pulmonary Disease, Pharmacy

Amongst the two, the solutions segment is estimated to hold the highest market share.\nBy Product, the market is classified as inhalers and nebulizers.

Key Points: 
  • Amongst the two, the solutions segment is estimated to hold the highest market share.\nBy Product, the market is classified as inhalers and nebulizers.
  • Amongst the two, the inhalers segment is estimated to hold the highest market share.\nBy Application, the market is classified as asthma and chronic obstructive pulmonary disease (COPD).
  • Amongst the two, the asthma segment is estimated to hold the highest market share.\nBy Distribution Channel, the market is classified as hospital pharmacies, retail pharmacies, and online channels.
  • Amongst all, hospital pharmacies are estimated to hold the highest market share.\nBy End Use, the market is classified as patients, R&D, and others.

PAOG Advances CBD Pharmaceutical Developments Backed By US Patent

Retrieved on: 
Thursday, April 8, 2021
Herbalism, Medicinal plants, Health sciences, Chronic lower respiratory diseases, Health, Medicine, Cannabis, Euphoriants, Medical cannabis, COPD: Journal of Chronic Obstructive Pulmonary Disease, CBD, Chronic obstructive pulmonary disease

RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.

Key Points: 
  • RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • PAOG is working with Veristat , a contract research organization (CRO), dedicated to the clinical advance of therapies and treatments through regulatory approval.
  • PAOG anticipates soon announcing new breakthroughs in its CBD RespRx pharmaceutical research.
  • Next week, on Tuesday, PAOG will release a similar update on its CBD Pharmaceutical Development Program.

PAOG U.S. Patent Backed CBD Pharmaceutical Development Remains On Track

Retrieved on: 
Thursday, April 8, 2021
Herbalism, Medicinal plants, Health sciences, Health, Chronic lower respiratory diseases, Medicine, COPD: Journal of Chronic Obstructive Pulmonary Disease, Cannabis, Chronic obstructive pulmonary disease, Medical cannabis, CBD

SANDUSKY, Ohio, April 8, 2021 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today announced a management update on the company's ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021.

Key Points: 
  • SANDUSKY, Ohio, April 8, 2021 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today announced a management update on the company's ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021.
  • RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • PAOG is working with Veristat , a contract research organization (CRO), dedicated to the clinical advance of therapies and treatments through regulatory approval.
  • PAOG anticipates soon announcing new breakthroughs in its CBD RespRx pharmaceutical research.